Your Thursday Update On Nasdaq Profile (BSGM)
$13.00 Laidlaw & Company Price Target
BSGM had an interesting day yesterday. Let's start from the beginning...
Just after the opening bell, BSGM dropped this press release:
BioSig Completes 1000 Patient Cases with its Signal Processing System for Electrophysiology
- The Company recently increased its procedural volume targets due to accelerated technology usage
- BioSig expands its commercial team to target technology adoption across three strategic regions
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that physicians have completed 1000 patient cases with its technology across nine installation sites.
Read the full article here.
As this press release continues to make the rounds in the days ahead, it could draw some serious attention from parties that don't know how game-changing the PURE EP System product could be.
BSGM Technical Update
Keeping an eye on BSGM during post-market hours, it bounced back over $4.00 which could be a major sign of things to come.
If potential support builds at that level, BSGM could once again try to make a push towards/past its 200-Day Simple Moving Average (SMA) like it did yesterday.
Furthermore, at close yesterday, Barchart was reporting BSGM to be trading over multiple lines of potential support:
- 20-Day SMA
- 50-Day SMA
- 5-Day EMA
- 13-Day EMA
That's huge after yesterday's pull back. This could mean that strong potential support could be holding at those levels.
If that's the case, BSGM might try to make a move back towards yesterday's high of $4.58 in the near term.
Additionally, the Barchart website is reporting a "BUY" recommendation for BSGM's composite "TrendSpotter" technical indicator.
Take a minute now before the market is open and read my initial BSGM report below.
*BioSig Technologies, Inc. (BSGM)*
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.
The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Here’s Why PURE EP Could Be a Game-Changer
According to XTalks, PURE EP could fill a significant need because:
“The electrograms used today can be riddled with noise and artifacts coming from other equipment found in the operating room. Such a procedure can take up to six hours, potentially yielding what is referred to in the industry as a ‘dirty signal’ that’s indiscernible to interpret by many electrophysiologists.” (1)
BioSig's PURE EP was developed to address unmet needs in a large and growing market and deliver technology to improve catheter ablation treatments for arrhythmias, Atrial Fibrillation, and Ventricular Tachycardia.
“The system is intended to acquire, digitize, amplify, filter, measure and calculate, display, record and store electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory under the supervision of licensed healthcare practitioners who are responsible for interpreting the data,” as further reported XTalks. (1)
No. 1 Potential Immediate Term Catalyst - Company's Tech To Be Featured At Stanford Retreat
BioSig’s Signal Processing Technology for Electrophysiology To Be Featured During 2021 Stanford Biodesign New Arrhythmia Technologies Retreat
Westport, CT, June 28, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company would be presenting during 2021 Stanford Biodesign New Arrhythmia Technologies Retreat, due to take place virtually on July 27, 2021. The Company will present at 2 pm PT.
Read the full article here.
No. 2 Potential Immediate Term Catalyst - Potential Squeeze On Horizon?
Check out BSGM's 6-month chart below: